Action RCUS ARCUS BIOSCIENCES, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Arcus Biosciences, Inc.

Actions

RCUS

US03969F1093

Temps réel estimé Cboe BZX
Autres places de cotation
 16:43:47 12/06/2024 		Varia. 5j. Varia. 1 janv.
15,6 USD -0,32 % Graphique intraday de Arcus Biosciences, Inc. -3,81 % -18,01 %
10/06 Arcus achève le recrutement des patients pour l'essai de phase 3 d'un régime contenant du domvanalimab pour le cancer de l'estomac MT
03/06 ARCUS BIOSCIENCES, INC. : Opinion positive de Citigroup ZM

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Arcus Biosciences Announces New Employment Inducement Grants
BU
Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers
BU
Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
BU
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
BU
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
BU
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
BU
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
BU
Arcus Biosciences Announces New Employment Inducement Grants
BU
ARC-9: A Randomized Study to Evaluate Etrumadenant Based Treatment Combinations in Previously Treated Metastatic Colorectal Cancer (mCRC) - Form 8-K
PU
Arcus Biosciences Announces New Employment Inducement Grants
BU
Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update
BU
Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024
BU
Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
BU
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update
BU
Arcus Biosciences Announces New Employment Inducement Grants
BU
Arcus Biosciences Announces New Employment Inducement Grants
BU
Arcus Biosciences Announces New Employment Inducement Grants
BU
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
BU
Arcus Biosciences Announces New Employment Inducement Grants
BU
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update
BU
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action RCUS
  4. Actualités Arcus Biosciences, Inc.
  5. Communiqués